文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺近距离放疗走向衰落?加拿大安大略省局限性前列腺癌根治性治疗的趋势与差异

Is prostate brachytherapy a dying art? Trends and variation in the definitive management of prostate cancer in Ontario, Canada.
PubMed 文献 · Radiother Oncol · 2020-07-24

该研究基于加拿大安大略省2006—2017年行政数据,纳入61,288例接受初始根治性治疗的局限性前列腺癌男性。多因素回归显示近距离放疗 boost 使用几率每年增加24%,近距离放疗单药每年增加3%,前列腺切除术每年下降6%,外照射放疗(EBRT)与治疗年份无显著关联;首诊放疗科医生是否开展近距离放疗显著影响治疗选择,且存在明显地理、提供者和患者差异。

要点

  • 近距离放疗 boost 使用几率每年增加24%(OR 1.24,95%CI 1.22-1.26,p<0.01)。
  • 近距离放疗单药每年增加3%(OR 1.03,95%CI 1.02-1.04,p<0.01),前列腺切除术每年下降6%(OR 0.94,95%CI 0.93-0.95,p<0.01)。
  • 首诊放疗科医生开展近距离放疗时,选择近距离放疗单药而非EBRT的OR为5.66(95%CI 5.11-6.26,p<0.01)。

核心结论

  • 研究发现近距离放疗使用率增加,主要由近距离放疗 boost 使用增加驱动;据作者所知,这是剂量递增EBRT时代首次报告近距离放疗使用增加。

研究设计与样本

  • 基于加拿大安大略省行政数据的回顾性队列研究,纳入2006—2017年诊断并接受初始根治性治疗的局限性前列腺癌男性61,288例。

主要发现

  • 多因素回归显示近距离放疗 boost 使用几率每年增加24%(OR 1.24,95%CI 1.22-1.26,p<0.01)。
  • 近距离放疗单药使用几率每年增加3%(OR 1.03,95%CI 1.02-1.04,p<0.01)。
  • 前列腺切除术使用几率每年下降6%(OR 0.94,95%CI 0.93-0.95,p<0.01)。
  • 治疗年份在外照射放疗(EBRT)的多因素模型中不显著。
  • 在仅限接受放疗者的多因素模型中,若首诊放疗科医生开展近距离放疗,选择近距离放疗单药而非EBRT的OR为5.66(95%CI 5.11-6.26,p<0.01),选择近距离放疗 boost 而非单纯EBRT的OR为2.88(95%CI 2.60-3.19,p<0.01)。

临床怎么用

  • 首诊放疗科医生是否开展近距离放疗与患者接受近距离放疗的几率显著相关,提示提供者因素影响治疗选择。
  • 研究中观察到治疗接受存在明显的地理、提供者和患者差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Declining prostate brachytherapy utilization has been reported in several studies, despite strong evidence for efficacy and safety compared to alternatives. We sought to evaluate contemporary trends in brachytherapy, external beam radiotherapy (EBRT) and prostatectomy utilization in a publicly funded healthcare system. MATERIALS AND METHODS: Men with localized prostate cancer diagnosed and treated between 2006 and 2017 in Ontario, Canada were identified using administrative data. Men received EBRT, brachytherapy (monotherapy or boost) or prostatectomy as initial definitive management. Multivariable logistic regression evaluated patient-, tumour-, and provider-factors on treatment utilization. RESULTS: 61,288 men were included. On multivariable regression, the odds of receiving brachytherapy boost increased 24% per year (odds ratio [OR]:1.24, 95% CI 1.22-1.26, p < 0.01), brachytherapy monotherapy increased 3% per year (OR:1.03, 95% CI:1.02-1.04, p < 0.01), and prostatectomy declined by 6% per year (OR:0.94, 95% CI 0.93-0.95, p < 0.01). Treatment year was not significant on multivariable modelling of EBRT. In a separate multivariable model limited to those who received radiotherapy, if the first radiation oncologist seen performed brachytherapy, the OR of receiving brachytherapy monotherapy over EBRT was 5.66 (95% CI: 5.11-6.26, p < 0.01) and 2.88 (95% CI: 2.60-3.19, p < 0.01) for brachytherapy boost over EBRT alone. Substantial geographic, provider and patient variation in treatment receipt was observed. CONCLUSION: We found increasing brachytherapy utilization, largely driven by increasing utilization of brachytherapy boost. To our knowledge, this is the first report of increasing brachytherapy use in the era of dose escalated EBRT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Corkum MT, Morton G, Louie AV, et al. Is prostate brachytherapy a dying art? Trends and variation in the definitive management of prostate cancer in Ontario, Canada. Radiother Oncol. 2020. PMID: 32717361. doi:10.1016/j.radonc.2020.07.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。